Key result
SGLT2 inhibitors reduce HHF, CV death, and CKD progression regardless of diabetes or baseline biomarkers.
Why the study?
This article aims to address the metabolic paradigm and cellular metabolism by reviewing clinical trials of SGLT2 inhibitors in heart failure, uncovering mechanisms of action, and describing effects on prognostic markers.
Do SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalizations in patients with heart failure?
Do SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalizations in patients with heart failure?
This review highlights the paradigm shift in heart failure management toward metabolic targets, confirming the robust cardiovascular and renal benefits of SGLT2 inhibitors.
Supports SGLT2 inhibitor use across heart failure phenotypes; extends prior evidence while leaving biomarker-guided selection open.
The sodium-glucose co-transporter-2-inhibitors (SGLT2I) recently gained a unique role in managing the heart failure reduced ejection fraction. These inhibitors reduce cardiovascular (CV) risk factors, including plasma glucose, blood pressure, albuminuria, body weight, and renal events in the long term. The clinical trials proved their role in reducing hospitalization for HF, CV and all-cause mortality, atherosclerosis-related events, and CKD progression. Initiating this medication on decompensated heart failure or post-discharge reduces the risk of re-hospitalization. These co-transporter inhibitors reduced heart failure and kidney events regardless of baseline biomarker concentration or diabetes mellitus status. This article aims to the metabolic paradigm and cellular metabolism by exposing the available clinical trials of this novel therapy for heart failure, uncovering the possible mechanisms of action on the CV system, and describing the positive effect on prognostic markers as pro-BNP, as well as changing the plasma renin-aldosterone activity, cardiac troponin T (hs-cTnT), and insulin-like growth factor-binding protein 7 (IGFBP7).
No takes yet. Share an insight, caveat, or question.
Shaban et al. (2022) conducted a review in Heart Failure (n=71,000). SGLT2 inhibitors vs. Placebo was evaluated. SGLT2 inhibitors reduce hospitalization for heart failure, cardiovascular mortality, and chronic kidney disease progression regardless of baseline biomarker concentration or diabetes mellitus status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: